Mannkind Nasal Inhaler with AVP-825 Nose piece

[madog365]

Thought this deserves it's own discussion thread as it hasn't been posted before. 
The Mannkind Nasal Inhaler FDA registration page has been updated with the following:


Afrezza; Commercial Inhaler, Gen2; AVP-825 Nose piece disposable inhaler



So what is AVP-825?

AVP-825,will also have a unique delivery mechanism. The mechanism is akin to traditional nasal inhalants, but the delivery actually uses the patient’s own breath to blow the medication up the nose. By using the patient’s breath, Palekar said, more medicine will actually get to where it’s supposed to go rather than ending up in the patient’s throat.
“By using the body’s properties, it will cause the throat to close when blown and deliver more drug to the nasal cavity than traditional nasal sprays,” Palekar said.


A company called Avanir is using this unique delivery method they created for an approved Acute Treatment of Migraine in Adults. In their drug pipeline is a method for treating Alzheimers agitation through nasal inhalation. 

SO - what then is Mannkind doing with it? For those who have seen some of my previous posts i think you know where i am going with this. For those who didn't you can google SNIFF Study or ACT Study for Alzheimers and Dementia Patients. 

Screen capture i took in January: imgur.com/Ti7xJrj
Page today: accessdata.fda.gov/scrIpts/cdrh/cfdocs/cfRL/rl.cfm?lid=430594&lpcd=KCO

[cm5]

SNIFF Study:   www.nia.nih.gov/alzheimers/clinical-trials/study-nasal-insulin-fight-forgetfulness-sniff

[cm5]

Flogging another horse running in the Chinese race against the ravages of diabetes---

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.

Chen Z1, Zhong C.

Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China.

Perturbed cerebral glucose metabolism, an invariant pathophysiological feature of AD, may be a critical contributor to the pathogenesis of this disease

We conclude that glucose metabolism abnormality plays a critical role in AD pathophysiological alterations through the induction of multiple pathogenic factors such as oxidative stress, mitochondrial dysfunction, and so forth. To clarify the causes, pathogeneses and consequences of cerebral hypometabolism in AD will help break the bottleneck of current AD study in finding ideal diagnostic biomarker and disease-modifying therapy.

[seanismorris]

I think inhalation (orally) is superior to nasally.

I may be biased but snorting a drug sounds extremely unpleasant; patient compliance would be a big issue.

If you think using Afrezza when having a cold would be difficult, imagine nasally.